Antag Therapeutics

CompanyDenmark

Antag Therapeutics develops one asset, in phase 1 (AT7687 in obesity). Mostly peptide acting on GIPR; based in Denmark.

1
Asset
Furthest stage: Phase 1; 0
Trials: 1
Signal

Pipeline

1

AT7687
Blocks the glucose-dependent insulinotropic polypeptide receptor to treat obesity.
Phase 1, Peptide, GIPR, obesity

Full company profiles: pipeline, trials, funding and people.

In the full profile

Evidence behind the mechanisms2
Signals2
Similar companies6

Papers

First-in-Human Study Demonstrates GIP Receptor (GIPR) Antagonist AT7687 as Well-Tolerated and Suitable for Once-Weekly Subcutaneous Injection for Treatment in People Living with Obesity
ADA Scientific Sessions 2026 abstract, 7 Jun 2026